aTyr Pharma Signs Equity Financing Agreement

aTyr Pharma, a biotherapeutics company, has entered into a definitive securities purchase agreement with certain institutional, and other accredited investors, including members of the company’s board of directors. The private placement is being led by Viking Global Investors with participation from EcoR1 Capital and Redmile Group. Gross proceeds from the private placement are expected to be approximately $45.8 million.

The company said it will use the proceeds from the transaction primarily to advance its pipeline of innovative therapeutic candidate programs based on its knowledge of the Resokine pathway, and for general corporate purposes.

Leave A Reply

Your email address will not be published.